Cognitive functions in long-term survivors of ovarian cancer

Gynecologic Oncology

Volumn 119, Issue 2, 2010, Pages 366-369

  Correa, Denise D ^a   Zhou, Qin ^a   Thaler, Howard T ^a   Maziarz, Michelle ^a   Hurley, Karen ^a   Hensley, Martee L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy adverse effects; Cognitive; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; ATTENTION; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVOR; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; HUMAN; MEMORY; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; CHEMICALLY INDUCED; CROSS-SECTIONAL STUDY; MIDDLE AGED; OVARIAN NEOPLASMS; PSYCHOLOGY; SURVIVOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OVARIAN NEOPLASMS; SURVIVORS;

EID: 77957749641     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.06.023     Document Type: Article

References (28)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics 2009 CA Cancer J Clin 59 2009 225 249
2. W.P. McGuire, W.J. Hoskins, and M.F. Brady Cyclophosphamide and cisplatin compared with cisplatin and paclitaxel in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6
3. R.F. Ozols Update on the management of ovarian cancer Cancer J 2 Suppl 2002 S22 S30
4. A.E. Kayl, and C.A. Meyers Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients Curr Opin Obstet Gynecol 18 2006 24 28
5. T.A. Ahles, A.J. Saykin, and C.T. Furstenberg Neuropsychological impact of standard-dose chemotherapy in long-term survivors of breast cancer and lymphoma J Clin Oncol 20 2002 485 493
6. C.B. Brezden, K.A. Phillips, M. Abdolell, T. Bunston, and I.F. Tannock Cognitive function in breast cancer patients receiving adjuvant chemotherapy J Clin Oncol 18 2000 2695 2701
7. S.B. Schagen, F.S. van Dam, and M.J. Muller Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma Cancer 85 1999 640 650
8. K.A. Donovan, B.J. Small, M.A. Andrykowski, F.A. Schmitt, P. Munster, and P.B. Jacobsen Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early stage breast carcinoma Cancer 104 2005 2499 2507
9. A. Scherwath, A. Mehnert, B. Schleimer, L. Schirmer, F. Fehlauer, and R. Kreienberg Neuropsychological function in high risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term effects Ann Oncol 17 2006 415 423
10. T.A. Ahles, A.J. Saykin, and B.C. McDonald Cognitive function in breast cancer patients prior to adjuvant treatment Breast Cancer Res Treat 110 2008 143 152
11. V. Jenkins, V. Shilling, and G. Deutsch A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer Br J Cancer 94 2006 828 834
12. J.S. Wefel, R. Lenzi, and R.L. Theriault The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial Cancer 100 2004 2292 2299
13. K. Mayerhofer, B. Bodner-Adler, and K. Bodner A paclitaxel-containing chemotherapy does not cause central nervous adverse effects: a prospective study in patients with ovarian cancer Anticancer Res 20 2000 4051 4056
14. M.L. Hensley, D.D. Correa, and H. Thaler Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning Gynecol Oncol 102 2006 270 277
15. D. Wechsler Wechsler Adult Intelligence Scale 3rd ed. 1997 The Psychological Corporation New York
16. D. Schretlen Brief Test of Attention. Psychological Assessment Resources. 1997
17. R.M. Reitan Validity of the trail making test as an indication of organic brain damage Percept Mot Skills 8 1958 271 276
18. R.H.B. Bennedict, D. Schretlen, L. Groninger, and J. Brandt Hopkins Verbal Learning Test-Revised: normative data and analysis of inter-form and test-retest reliability Clin Neuropsychol 12 1998 43 55
19. D.J. Scheretlen, S.M. Tesca, and J.M. Winicki Frequency and bases of abnormal performance of healthy adults on neuropsychological testing J Int Neuropsychol Soc 14 2008 436 445
20. T.H. Yamada, N.L. Denburg, and L.J. Beglinger Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy J Neuropsychiatry Clin Neurosci 22 2010 48 54
21. M.K. Tuxen, and H.S. Werner Neurotoxicity secondary to antineoplastic drugs Cancer Treat Rev 20 1994 191 214
22. T.A. Ahles, and A.L. Saykin Candidate mechanisms for chemotherapy-induced cognitive changes Nat Rev Cancer 7 2007 192 201
23. J. Dietrich, R. Han, and Y. Yang CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and vivo J Biol 5 2006 1 23
24. M. Inagaki, E. Yoshikawa, and Y. Matsuoka Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy Cancer 109 2007 146 156
25. T.A. Ahles, A.J. Saykin, and W.W. Noll The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy Psychooncology 12 2003 612 619
26. L.T. Shuster, B.S. Gostout, and B.R. Grossardt Prophylactic oophorectomy in pre-menopausal women and long term health - a review Menopause Int 14 2008 111 116
27. C.M. Schilder, and S.B. Schagen Effects of hormonal therapy on cognitive functioning in breast cancer patients: review of the literature Minerva Ginecol 59 2007 387 401
28. C.M. Schilder, C. Seynaeve, and L.V. Beex Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial J Clin Oncol 28 2010 1294 1300